Compare FAST & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAST | INSM |
|---|---|---|
| Founded | 1967 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | FAST | INSM |
|---|---|---|
| Price | $41.68 | $205.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $44.61 | ★ $178.71 |
| AVG Volume (30 Days) | ★ 6.6M | 2.7M |
| Earning Date | 01-16-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 6.38 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $7,997,600,000.00 | $447,022,000.00 |
| Revenue This Year | $10.88 | $43.10 |
| Revenue Next Year | $8.98 | $128.25 |
| P/E Ratio | $39.06 | ★ N/A |
| Revenue Growth | 6.92 | ★ 30.34 |
| 52 Week Low | $35.31 | $60.40 |
| 52 Week High | $50.63 | $212.75 |
| Indicator | FAST | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 63.41 |
| Support Level | $39.81 | $202.27 |
| Resistance Level | $40.70 | $212.75 |
| Average True Range (ATR) | 0.74 | 6.77 |
| MACD | 0.35 | -0.89 |
| Stochastic Oscillator | 88.75 | 70.56 |
Fastenal began as an industrial retailer, expanding its product portfolio from nuts and bolts to cutting tools, safety equipment, and janitorial supplies. It transitioned into a distributor by building out a dense network of branches close to its business customers. Once a customer becomes large enough, Fastenal installs vending machines and its own personnel on-site. Today, these on-site locations exceed Fastenal's branch count and remain the firm's main focus for expansion. Fastenal acts as a one-stop outsourcing partner for its industrial customers, offering value-added services along with a wide breadth of maintenance, repair, and operations supplies.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.